摘要
目的:研究经131I治疗后的格雷夫斯病(Graves disease,GD)病人发生甲状腺功能减退症(甲减)的相关危险因素。方法:对临床确诊的150例GD病人给予131I治疗,分析治疗后甲减与年龄、性别、病程、治疗前甲状腺质量、甲状腺最高摄131I率、每克甲状腺组织的摄131I剂量及131I总剂量、TGA、TMA的关系。结果:甲减组与非甲减组年龄、性别、病程、每克甲状腺组织的摄取131I剂量无显著性差异,两组间的治疗前甲状腺质量、甲状腺最高摄131I率及131I总剂量等因素有显著性差异。结论:131I治疗GD病人甲减的发生与治疗前甲状腺质量、甲状腺最高摄131I率及131I总剂量、TGA、TMA有关,与年龄、性别、病程、每克甲状腺组织的摄取剂量无关。
Objective：To observe correlated risk factors about hypothyroidism after ^131Ⅰ treated in Graves disease（GD） patients. Methods： 150 clinical defined GD patients were treated with ^131Ⅰ,analysed correlation among hypothyroidism and age, sex, course of disease, pretherapeutic mass of thyroid gland, maximum ^131Ⅰ uptake of thyroid, ^131Ⅰ uptake dose per gram of thyroid gland, total ^131Ⅰ dose, thyroglobulin antibody （ TGA）, thyroid microsomal antibody （ TMA ） etc. Results： There was no significant difference in age, sex, course of disease, ^131Ⅰ uptake dose per gram of thyroid gland between the hypothyroidism group and non -hypothyroidism group, But there was significant difference in pretherapeutic mass of thyroid gland, maximum ^131Ⅰ uptake of thyroid, total ^131Ⅰ uptake dose, TGA, TMA between two groups. Conclusion： Pretherapeutic mass of thyroid gland,maximum ^131Ⅰ uptake of thyroid, total ^131Ⅰ dose, TGA, TMA are correlated with hypothyroidism in GD patients treated with ^131Ⅰ, but hypothyroidism is not related to age, sex, course of disease and ^131Ⅰ uptake dose per gram of thyroid gland.
出处
《内蒙古医学院学报》
2009年第2期123-126,共4页
Acta Academiae Medicinae Neimongol
基金
内蒙古自治区科技计划项目(2008)
